Research location

Hollywood

Florida, United States

Published trials768
Site observations821
Linked trials published768
Page1 / 16

Research activity in Hollywood

Florida, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 768 trials and 821 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Hollywood

768 linked trials · page 1 of 16
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNCT07668414 · 2026-09-22 · 2 site observations
RECRUITING
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461 · 2026-08-24 · 1 site observation
RECRUITING
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsNCT07797335 · 2026-08-24 · 1 site observation
RECRUITING
Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaNCT07686263 · 2026-08-20 · 1 site observation
RECRUITING
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive DisorderNCT07775300 · 2026-08-14 · 1 site observation
RECRUITING
A Study of LTX-001 In Adult Participants With Acute Exacerbation of SchizophreniaNCT07734493 · 2026-08-03 · 2 site observations
RECRUITING
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213 · 2026-07-06 · 1 site observation
RECRUITING
Phase 1b/2 Study of IV Sarilumab in Adult With RANCT07704580 · 2026-07-02 · 1 site observation
RECRUITING
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388 · 2026-06-22 · 1 site observation
RECRUITING
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic DysfunctionNCT07192952 · 2026-06-01 · 1 site observation
RECRUITING
52-week Open Label Safety-Tolerability StudyNCT07369154 · 2026-04-23 · 1 site observation
RECRUITING
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsNCT07565428 · 2026-04-23 · 1 site observation
RECRUITING
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesNCT07415954 · 2026-04-17 · 1 site observation
RECRUITING
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630 · 2026-04-13 · 1 site observation
RECRUITING
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsNCT07424404 · 2026-04-07 · 1 site observation
RECRUITING
A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaNCT07459647 · 2026-03-31 · 2 site observations
RECRUITING
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)NCT07202546 · 2026-02-11 · 1 site observation
RECRUITING
A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507 · 2026-02-10 · 1 site observation
RECRUITING
A Study of Brenipatide in Adult Participants With Major Depressive DisorderNCT07412756 · 2026-02-09 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)NCT07288567 · 2026-01-29 · 1 site observation
RECRUITING
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.NCT07494305 · 2026-01-23 · 1 site observation
RECRUITING
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney DiseaseNCT07271186 · 2026-01-09 · 1 site observation
RECRUITING
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 · 2026-01-08 · 1 site observation
RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive DisorderNCT07276997 · 2025-12-18 · 1 site observation
RECRUITING
Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaNCT07227818 · 2025-12-16 · 1 site observation
RECRUITING
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic DysfunctionNCT07188805 · 2025-11-19 · 1 site observation
RECRUITING
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseNCT07284667 · 2025-11-14 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24 · 1 site observation
RECRUITING
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationNCT07177339 · 2025-10-20 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation
RECRUITING
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTNCT07061288 · 2025-09-03 · 1 site observation
RECRUITING
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With SchizophreniaNCT07191483 · 2025-08-27 · 1 site observation
RECRUITING
A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot UlcersNCT07159282 · 2025-08-26 · 1 site observation
RECRUITING
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaNCT07105098 · 2025-08-11 · 1 site observation
RECRUITING
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068 · 2025-08-06 · 1 site observation
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 2 site observations
RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaNCT07114874 · 2025-07-11 · 1 site observation
RECRUITING
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation
RECRUITING
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.NCT06846281 · 2025-06-23 · 1 site observation
RECRUITING
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisNCT06972446 · 2025-06-20 · 1 site observation
RECRUITING
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28 · 1 site observation
RECRUITING
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaNCT06963034 · 2025-05-08 · 1 site observation
RECRUITING
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06966401 · 2025-04-16 · 1 site observation
RECRUITING
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06911112 · 2025-03-31 · 1 site observation
RECRUITING
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942 · 2025-03-19 · 2 site observations
RECRUITING
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation
RECRUITING
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06786624 · 2025-01-22 · 1 site observation
RECRUITING
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)NCT06524830 · 2024-12-30 · 1 site observation
RECRUITING
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionNCT06736574 · 2024-12-19 · 1 site observation
RECRUITING

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.